"Manifold Bio Announces Strategic Collaboration with Roche to Advance AI-Driven Neurological Drug Discovery"

"Manifold Bio has entered a strategic research collaboration and licensing agreement with Roche to develop advanced blood-brain barrier (BBB) shuttles for treating neurological and neurodegenerative diseases. The partnership leverages Manifold's AI-driven drug discovery platform and proprietary tissue-targeting technologies. Legal counsel for the transaction was provided by Latham & Watkins."

Latham & Watkins participated in the transaction, advising Manifold Bio in its strategic research collaboration and license agreement with Roche. The transaction involves a partnership between Manifold Bio, a platform therapeutics company pioneering AI-guided drug discovery, and Roche to apply Manifold's proprietary tissue-targeting shuttle portfolio and mDesign AI-driven in vivo discovery engine to develop next-generation BBB shuttles for neurological and neurodegenerative disease treatments. The Latham & Watkins team included Bay Area partner Kate Hillier (corporate), associate Arun Mohan (corporate), New York partner John Pierce (arbitration), Bay Area partner Grace Lee (tax), and associate Derek Gumm (tax).

"Manifold Bio Announces Strategic Collaboration with Roche to Advance AI-Driven Neurological Drug Discovery"

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads